论文部分内容阅读
目的探讨福辛普利联合美托洛尔对冠心病心力衰竭患者心功能的影响。方法选取2012年6月至2014年1月120例冠心病心力衰竭患者,将其随机分为对照组和试验组,每组60例。两组均给予常规疗法,对照组给予福辛普利,试验组给予福辛普利联合美托洛尔,连续服用12个月。分别在入院和治疗后12个月时检测心功能分级、心胸比率,同时比较左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)、左心室射血分数(LVEF)。结果治疗12个月后两组心功能分级、心率、心胸比率、LVEDD、LVESD以及LVEF均显著改善(P<0.05);试验组上述指标改善情况好于对照组,差异有统计学意义(P<0.05)。结论福辛普利联合美托洛尔能够改善冠心病心力衰竭患者的心功能,为心力衰竭的临床诊疗提供依据。
Objective To investigate the influence of fosinopril combined with metoprolol on cardiac function in patients with coronary heart disease and heart failure. Methods 120 patients with CHD from June 2012 to January 2014 were randomly divided into control group and experimental group with 60 cases in each group. Both groups were given conventional therapy, the control group was given fosinopril, the trial group was given fosinopril combined with metoprolol, taking 12 consecutive months. Cardiac function classification and cardiothoracic rate were detected at admission and 12 months after treatment. LVEDD, LVESD and LVEF were also compared. Results After 12 months treatment, heart function grading, heart rate, cardiothoracic ratio, LVEDD, LVESD and LVEF in both groups were significantly improved (P <0.05). The improvement of the above indexes in the experimental group was better than that in the control group (P < 0.05). Conclusion Fosinopril combined with metoprolol can improve cardiac function in patients with heart failure and provide basis for the clinical diagnosis and treatment of heart failure.